Therapeutic Effect of CD137 Immunomodulation in Lymphoma and Its Enhancement by Treg Depletion

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2009 Jul 31

PMID 19641184

Citations 78

Authors

Roch Houot

Matthew J Goldstein

Holbrook E Kohrt

June H Myklebust

Ash A Alizadeh

Jack T Lin

Jonathan M Irish

James A Torchia

Arne Kolstad

Lieping Chen

Ronald Levy

Affiliations

Soon will be listed here.

Abstract

Despite the success of passive immunotherapy with monoclonal antibodies (mAbs), many lymphoma patients eventually relapse. Induction of an adaptive immune response may elicit active and long-lasting antitumor immunity, thereby preventing or delaying recurrence. Immunomodulating mAbs directed against immune cell targets can be used to enhance the immune response to achieve efficient antitumor immunity. Anti-CD137 agonistic mAb has demonstrated antitumor efficacy in various tumor models and has now entered clinical trials for the treatment of solid tumors. Here, we investigate the therapeutic potential of anti-CD137 mAb in lymphoma. We found that human primary lymphoma tumors are infiltrated with CD137+ T cells. We therefore hypothesized that lymphoma would be susceptible to treatment with anti-CD137 agonistic mAb. Using a mouse model, we demonstrate that anti-CD137 therapy has potent antilymphoma activity in vivo. The antitumor effect of anti-CD137 therapy was mediated by both natural killer (NK) and CD8 T cells and induced long-lasting immunity. Moreover, the antitumor activity of anti-CD137 mAb could be further enhanced by depletion of regulatory T cell (T(regs)). These results support the evaluation of anti-CD137 therapy in clinical trials for patients with lymphoma.

Citing Articles

Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8 T cells in cis and in trans.

Liu L, Chen F, Li S, Yang T, Chen S, Zhou Y Sci Adv. 2024; 10(34):eadp8647.

PMID: 39178257 PMC: 11343023. DOI: 10.1126/sciadv.adp8647.

Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin's lymphoma.

Ma Y, Luo F, Zhang Y, Liu Q, Xue J, Huang Y Cell Rep Med. 2024; 5(2):101414.

PMID: 38330942 PMC: 10897605. DOI: 10.1016/j.xcrm.2024.101414.

The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy.

Mejia-Guarnizo L, Monroy-Camacho P, Turizo-Smith A, Rodriguez-Garcia J Front Immunol. 2024; 14:1298571.

PMID: 38162657 PMC: 10757365. DOI: 10.3389/fimmu.2023.1298571.

Modeling the crosstalk between malignant B cells and their microenvironment in B-cell lymphomas: challenges and opportunities.

Brauge B, Dessauge E, Creusat F, Tarte K Front Immunol. 2023; 14:1288110.

PMID: 38022603 PMC: 10652758. DOI: 10.3389/fimmu.2023.1288110.

Channeling the Natural Properties of Sindbis Alphavirus for Targeted Tumor Therapy.

Pampeno C, Hurtado A, Opp S, Meruelo D Int J Mol Sci. 2023; 24(19).

PMID: 37834397 PMC: 10573789. DOI: 10.3390/ijms241914948.

References

Lim H, Hillsamer P, Banham A, Kim C . Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol. 2005; 175(7):4180-3. DOI: 10.4049/jimmunol.175.7.4180. View

Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T . Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med. 2005; 202(7):885-91. PMC: 2213162. DOI: 10.1084/jem.20050940. View

Vu M, Xiao X, Gao W, Degauque N, Chen M, Kroemer A . OX40 costimulation turns off Foxp3+ Tregs. Blood. 2007; 110(7):2501-10. PMC: 1988917. DOI: 10.1182/blood-2007-01-070748. View

Choi B, Kim Y, Kang W, Lee S, Kim K, Shin S . Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res. 2007; 67(18):8891-9. DOI: 10.1158/0008-5472.CAN-07-1056. View

Maloney D . Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol. 2005; 23(26):6421-8. DOI: 10.1200/JCO.2005.06.004. View

Stokke T, Galteland E, Holte H, Smedshammer L, Suo Z, Smeland E . Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma. Int J Cancer. 2000; 89(4):313-24. DOI: 10.1002/1097-0215(20000720)89:4<313::aid-ijc1>3.0.co;2-d. View

Umetsu D, Esserman L, Donlon T, DeKruyff R, Levy R . Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones. J Immunol. 1990; 144(7):2550-7. View

Melero I, Murillo O, Dubrot J, Hervas-Stubbs S, Perez-Gracia J . Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 2008; 29(8):383-90. DOI: 10.1016/j.tips.2008.05.005. View

Elpek K, Lacelle C, Singh N, Yolcu E, Shirwan H . CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol. 2007; 178(11):6840-8. DOI: 10.4049/jimmunol.178.11.6840. View

10.

Wilcox R, Tamada K, Strome S, Chen L . Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol. 2002; 169(8):4230-6. DOI: 10.4049/jimmunol.169.8.4230. View

11.

Zhang B, Maris C, Foell J, Whitmire J, Niu L, Song J . Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent. J Clin Invest. 2007; 117(10):3029-41. PMC: 1974869. DOI: 10.1172/JCI32426. View

12.

Sugamura K, Ishii N, Weinberg A . Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol. 2004; 4(6):420-31. DOI: 10.1038/nri1371. View

13.

Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T, Nomura T . Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity. 2007; 27(1):145-59. DOI: 10.1016/j.immuni.2007.04.017. View

14.

Zhao D, Thornton A, DiPaolo R, Shevach E . Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood. 2006; 107(10):3925-32. PMC: 1895290. DOI: 10.1182/blood-2005-11-4502. View

15.

Shevach E, Stephens G . The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity?. Nat Rev Immunol. 2006; 6(8):613-8. DOI: 10.1038/nri1867. View

16.

Choi B, Bae J, Choi E, Kang W, Sakaguchi S, Vinay D . 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J Leukoc Biol. 2003; 75(5):785-91. DOI: 10.1189/jlb.1003491. View

17.

Melero I, Hervas-Stubbs S, Glennie M, Pardoll D, Chen L . Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007; 7(2):95-106. DOI: 10.1038/nrc2051. View

18.

Houot R, Levy R . T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood. 2008; 113(15):3546-52. PMC: 2668854. DOI: 10.1182/blood-2008-07-170274. View

19.

Zou W . Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005; 5(4):263-74. DOI: 10.1038/nrc1586. View

20.

Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang C, Angelo M . Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A. 2001; 98(26):15149-54. PMC: 64998. DOI: 10.1073/pnas.211566398. View